

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

WATSON LABORATORIES, INC.,
Petitioner,

v.

UNITED THERAPEUTICS, INC.,
Patent Owner.

Case No. IPR2017-01621
Patent No. 9,358,240

**PETITIONER'S COMBINED MOTION TO SUBMIT SUPPLEMENTAL
INFORMATION UNDER 37 C.F.R. § 42.123 AND MOTION FOR
ADDITIONAL DISCOVERY UNDER 37 C.F.R. §42.51**

Mail Stop PATENT BOARD
Patent Trial and Appeal Board
United States Patent and Trademark Office
PO Box 1450
Alexandria, Virginia 22313-1450
Submitted Electronically via PTAB E2E

TABLE OF CONTENTS

| | Page |
|--|------|
| I. INTRODUCTION | 1 |
| II. FACTUAL BACKGROUND..... | 1 |
| III. LEGAL STANDARDS | 3 |
| IV. MOTION TO SUBMIT SUPPLEMENTAL INFORMATION | 3 |
| A. The Proposed Supplemental Information is Relevant..... | 3 |
| B. Allowing the Supplemental Information Now Will Allow the Issue to be Decided on a Fully Developed Record. | 6 |
| V. MOTION FOR ADDITIONAL DISCOVERY | 7 |
| A. The Additional Discovery Will Lead to the Discovery of Useful Information. | 7 |
| B. The Additional Discovery Does Not Implicate Patent Owner’s Litigation Positions. | 8 |
| C. The Remaining Garmin Factors Support Granting Petitioner’s Motion for Additional Discovery | 10 |
| VI. CONCLUSION..... | 10 |

TABLE OF AUTHORITIES

Page(s)

Cases

Ethicon Endo-Surgery, Inc. v. Hologic, Inc.,
689 F. Supp. 2d 929 (S.D. Ohio 2010)4

Garmin Int’l, Inc. v. Cuozzo Speed Techs., LLC,
Case No. IPR2012–00001, Paper 26 (PTAB Mar. 5, 2013).....3, 8

Mylan v. Allergan,
Case No. IPR2016-01127, Paper 28 (PTAB May 31, 2017).....8

Riverwood Int’l Corp. v. R.A. Jones & Co., Inc.,
324 F.3d 1346 (Fed. Cir. 2003)4

Sprint Communications Co. L.P. v. Comcast IP Holdings, LLC,
No. 12–1013–RGA, 2015 WL 452289 (D. Del. Jan. 30, 2015).....4

Varian Med. Sys. v. Wm. Beaumont Hosp.,
IPR2016-163, Paper 79 (PTAB May 4, 2017)5

Statutes

35 U.S.C. § 102(a) 1

Other Authorities

37 C.F.R. § 42.51(b)(2)..... 3

37 C.F.R. § 42.51(b)(2)(i)..... 7

37 C.F.R. § 42.123(a)..... 3

37 C.F.R. § 42.123(a)(1)..... 6

Fed. R. Evid. 401 6

..

PETITIONER'S EXHIBIT LIST

| Exhibit | Description |
|---------|--|
| 1001 | U.S. Patent No. 9,358,240 |
| 1002 | Declaration of Maureen D. Donovan in Support of the Petition for Inter Partes Review of U.S. Patent No. 9,358,240 |
| 1003 | Robert Voswinckel, et al. "Inhaled treprostinil sodium for the treatment of pulmonary hypertension" Abstract #1414, <i>Circulation</i> , 110, 17, Supplement (Oct. 2004): III-295 ("Voswinckel") |
| 1004 | U.S. Patent Application Publication No. 2004/0265238 A1 to Chaudry ("Chaudry") |
| 1005 | Hossein Ardeschi Ghofrani, Robert Voswinckel, et al., "Neue Therapieoptionen in der Behandlung der pulmonalerteriellen Hypertonie," <i>Hertz</i> , 30,4 (June 2005): 296-302 ("Ghofrani") |
| 1006 | Opti-Neb-ir® Operating Instructions, Model ON-100/2 (2005) |
| 1007 | RESERVED |
| 1008 | Venta-Neb-ir® A-I-C-I Operating Instructions, Model VN-100/4 |
| 1009 | Annexes to Commission Decision C(2005)3436 of 05 September 2005, http://ec.europa.eu/health/documents/community-register/2005/2005090510259/anx_10259_en.pdf (Annex III – Ventavis® Labelling and Package Leaflet) |
| 1010 | U.S. Patent No. 6,606,989 ("Brand '989") |
| 1011 | Amendment and Reply Accompanying RCE filed in 12/591,200 (Jul. 2, 2013) (with accompanying Declaration of Lewis Rubin, M.D.) |
| 1012 | WO 93/00951 to Patton |
| 1013 | Declaration of Scott Bennett, Ph.D. |
| 1014 | Affidavit of Christopher Butler, June 15, 2017 |
| 1015 | Affidavit of Christopher Butler, June 16, 2017 |
| 1016 | RESERVED |
| 1017 | RESERVED |
| 1018 | U.S. Patent No. 6,521,212 ("Cloutier '212") |
| 1019 | U.S. Patent No. 4,306,075 ("Aristoff '075") |
| 1020 | U.S. Patent No. 5,190,972 ("Dumble '972") |
| 1021 | European Patent Specification 0347243 B1, published January 13, 1993 |
| 1022 | U.S. Patent No. 6,261,539 ("Adjei '539") |
| 1023 | European Patent Application Publication No. EP 0372777 A2 ("Purewal EP '777") |
| 1024 | U.S. Patent No. 4,895,719 ("Radhakrishnan '719") |

...

| | |
|------|--|
| 1025 | U.S. Patent No. 5,153,222 (“Tadepalli ’222”) |
| 1026 | U.S. Patent No. 6,357,671 (“Cewers ’671”) |
| 1027 | Gessler, et al., <i>Ultrasonic versus Jet Nebulization of Iloprost in Severe Pulmonary Hypertension</i> , Eur. Respiratory J., 17:14-19 (2001) |
| 1028 | Olschewski H., et al., <i>Aerosolized Prostacyclin and Iloprost in Severe Pulmonary Hypertension</i> , 1996 Ann. Intern. Med. 124(9), 820-824 (1996) (“Olschewski 199”) |
| 1029 | Olschewski, et al., <i>Pharmacodynamics and Pharmacokinetics of Inhaled Iloprost, Aerosolized by Three Different Devices, in Severe Pulmonary Hypertension</i> , Chest J., 124(4), 1294-1304 (Oct. 2003) |
| 1030 | Byron, <i>Drug Delivery Devices: Issues in Drug Development</i> , Proc. Am. Thorac. Soc., 1:321-328 (2004) |
| 1031 | U.S. Patent No. 5,544,646 (“Lloyd”) |
| 1032 | Edwards D.A. et al., <i>Recent Advances in Pulmonary Drug Delivery Using Large Porous Inhaled Particles</i> , Journal of Applied Physiology, 85(2): 379-385 (1998) (“Edwards 1998”) |
| 1033 | Badesch, et al., <i>Prostanoid Therapy for Pulmonary Arterial Hypertension</i> , J. of the Am. C. of Cardiology, 43(12):Suppl. S (2004) |
| 1034 | U.S. Patent No. 6,054,486 (“Crow ’486”) |
| 1035 | U.S. Food and Drug Administration, Drug Approval Package: Remodulin® (approved on May 21, 2002), http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-272_Remodulin.cfm (“Remodulin® Approval Package”) |
| 1036 | Electronic Medicines Compendium, Ventavis®, http://www.medicines.org.uk/emc/medicine/13743 |
| 1037 | <i>European Agency Approves Ventavis for Primary Pulmonary Hypertension</i> , P&T Community (Sep. 22, 2003), https://www.ptcommunity.com/news/2003-09-22-000000/european-agency-approves-ventavis-primary-pulmonary-hypertension |
| 1038 | EU Community Register of Medicinal Products, Homepage, http://ec.europa.eu/health/documents/community-register/html/index_en.htm |
| 1039 | EMA Scientific Discussion, Ventavis® (2004), http://www.ema.europa.edu/docs/en_GB/document_library/EPAR_Scientific_Discussion/human/000474/WC500048688.pdf |
| 1040 | Muller et al., “Use of Inhaled Iloprost in a Case of Pulmonary Hypertension during Pediatric Congenital Heart Surgery,” 99 Anesthesiology 743-747 (2003) |

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.